Search

Biologics are one of the fastest growing, most important, and most expensive segments of the pharmaceutical industry. The high price of biologics in the United States is making these life-saving drugs unaffordable for many Americans and creating unsustainable burdens on purchasers. While the EU has created an abbreviated approval process for biosimilars, there is no explicit legislative pathway in the United States that would enable generic competition for biologics. The Promoting Innovation and Access to Life-Saving Medicine Act would provide such a generic pathway for biologics, using competition to lower drug prices. The bill provides an appropriate balance between access to affordable medicine and retaining incentives for innovation. [ABSTRACT FROM AUTHOR]

Focuses on the crisis in community mental health care in the U.S. in 2006. Impact of the crisis on children; Challenges posed by the crisis to the public health community and the federal government; Recommendations for public health planning.

Presents a letter from U.S. Senator Henry A. Waxman to Christine Todd Whitman, administrator of the U.S. Environmental Protection Agency, regarding a pesticides conference as of December 2003.

Considers the development of the polio vaccine in April 1955 as a seminal public health achievement in the U.S. Key factors that made such breakthrough possible; Comments on the disparities in access to vaccination; Status of the continued efforts to eliminate human transmission of polio.